Nothing Special   »   [go: up one dir, main page]

Lu et al., 2013 - Google Patents

Viral–host interactions that control HIV-1 transcriptional elongation

Lu et al., 2013

View HTML
Document ID
2769951660216849416
Author
Lu H
Li Z
Xue Y
Zhou Q
Publication year
Publication venue
Chemical reviews

External Links

Snippet

Regulation of the pause and elongation by ribonucleic acid (RNA) polymerase II (Pol II) is used widely by metazoans to attain the pattern of gene expression that is essential for optimal cell growth/renewal, differentiation, and stress response. Currently, much of what we …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Similar Documents

Publication Publication Date Title
Lu et al. Viral–host interactions that control HIV-1 transcriptional elongation
Ott et al. The control of HIV transcription: keeping RNA polymerase II on track
Rice The HIV-1 Tat protein: mechanism of action and target for HIV-1 cure strategies
Imai et al. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294
Taube et al. Lost in transcription: molecular mechanisms that control HIV latency
Colin et al. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies
Margolis Mechanisms of HIV latency: an emerging picture of complexity
Kumar et al. HIV-1 latency in monocytes/macrophages
Creaven et al. Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat
Geis et al. Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced
Tsai et al. Epitranscriptomic addition of m6A regulates HIV-1 RNA stability and alternative splicing
Parolin et al. New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action
He et al. New insights into the control of HIV-1 transcription: when Tat meets the 7SK snRNP and super elongation complex (SEC)
Delannoy et al. Cat and mouse: HIV transcription in latency, immune evasion and cure/remission strategies
Bangham et al. Regulation of latency in the human T cell leukemia virus, HTLV-1
Khan et al. Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins
Victoriano et al. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy
Pessler et al. Reciprocal regulation of the nuclear factor of activated T cells and HIV-1
Chougui et al. HUSH, a link between intrinsic immunity and HIV latency
Peze-Heidsieck et al. Retrotransposons as a Source of DNA Damage in Neurodegeneration
Melkova et al. Current views on HIV-1 latency, persistence, and cure
Li et al. A minor subset of super elongation complexes plays a predominant role in reversing HIV-1 latency
Ranjbar et al. NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site
Zicari et al. DNA dependent protein kinase (DNA-PK) enhances HIV transcription by promoting RNA polymerase II activity and recruitment of transcription machinery at HIV LTR
Acchioni et al. Fighting HIV-1 persistence: At the crossroads of “shoc-K and B-Lock”